Insider Buying: NeuroSense Therapeutics (NASDAQ:NRSN) CFO Acquires 250,000 Shares of Stock

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) CFO Or Eisenberg acquired 250,000 shares of NeuroSense Therapeutics stock in a transaction that occurred on Tuesday, June 16th. The stock was acquired at an average cost of $0.80 per share, with a total value of $200,000.00. Following the completion of the purchase, the chief financial officer owned 1,504,050 shares in the company, valued at approximately $1,203,240. This represents a 19.94% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

NeuroSense Therapeutics Price Performance

NeuroSense Therapeutics stock traded up $0.01 during mid-day trading on Wednesday, hitting $0.71. The company’s stock had a trading volume of 228,051 shares, compared to its average volume of 174,519. The firm’s 50 day moving average is $0.78 and its 200 day moving average is $0.86. The company has a market cap of $22.95 million, a PE ratio of -1.31 and a beta of 1.56. NeuroSense Therapeutics Ltd. has a 52-week low of $0.63 and a 52-week high of $2.52.

Institutional Investors Weigh In On NeuroSense Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Two Sigma Investments LP purchased a new stake in shares of NeuroSense Therapeutics during the 3rd quarter worth about $26,000. Jane Street Group LLC purchased a new stake in shares of NeuroSense Therapeutics during the 2nd quarter worth about $54,000. Squarepoint Ops LLC raised its stake in shares of NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after purchasing an additional 45,450 shares in the last quarter. Finally, Yorkville Advisors Global LP bought a new position in shares of NeuroSense Therapeutics in the 4th quarter valued at approximately $77,000. 1.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on NRSN shares. D. Boral Capital reissued a “buy” rating and issued a $14.00 price objective on shares of NeuroSense Therapeutics in a research note on Wednesday, April 8th. Roth Mkm assumed coverage on NeuroSense Therapeutics in a research note on Tuesday, March 10th. They set a “buy” rating and a $3.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeuroSense Therapeutics in a research note on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $8.50.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.